Contract Win

IXICO plc

18 July 2023

 

18 July 2023

IXICO plc

("IXICO", the "Company" or the "Group")

Contract win for a Phase 3 Progressive Supranuclear Palsy (PSP) study;

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces that it has signed a contract with a new client. IXICO will provide its imaging services in a clinical trial of a novel therapeutic to treat Progressive Supranuclear Palsy, a rare neurodegenerative disease. The contract value is circa US$1.7m (circa £1.3m), over a 4-year term. The World Health Organization defines a rare disease as one that strikes fewer than 65 per 100,000 people.

 Giulio Cerroni, CEO of IXICO, commented: "Rare diseases are a global health priority with about 95% of all rare diseases not yet having treatments. This new contract exemplifies the traction we are building beyond our strong market position in HD into other rare neuro disorders to expand our market opportunities and acquire new clients in the dynamic field of rare neurological diseases¹."

¹National Organisation of Rare Diseases

For further information please contact:

IXICO plc	[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)		[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

END